# China NMPA Drug Inspection - Xinxing County Yongxiang Traditional Chinese Medicine Pieces Factory Co., Ltd. - Astragalus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/xinxing-county-yongxiang-traditional-chinese-medicine-pieces-factory-co-ltd/f7461fd3-3cda-41cf-95a0-7fb21a2e3921/
Source feed: China

> China NMPA drug inspection for Xinxing County Yongxiang Traditional Chinese Medicine Pieces Factory Co., Ltd. published June 02, 2017. Drug: Astragalus. An announcement by China's State Administration for Market Regulation, dated June 2, 2017 (Announcement No. 85 of 2017),

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 85 of 2017 from the State Administration of Traditional Chinese Medicine regarding 12 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Xinxing County Yongxiang Traditional Chinese Medicine Pieces Factory Co., Ltd.
- Publication Date: 2017-06-02
- Drug Name: Astragalus
- Inspection Finding: Properties are not up to standard
- Action Taken: Suspend sales and use, recall products, conduct rectification, seize and detain, and initiate investigation.
- Summary: An announcement by China's State Administration for Market Regulation, dated June 2, 2017 (Announcement No. 85 of 2017), reported that 12 batches of traditional Chinese medicine (TCM) decoction pieces were found to be substandard. Inspections by the China National Institutes for Food and Drug Control identified issues with Astragalus membranaceus produced by 12 companies, including Xuzhou Pengzu Traditional Chinese Medicine Decoction Pieces Co., Ltd., specifically citing defects in the product's "appearance." In response, provincial food and drug administrations were directed to take immediate action. These measures included seizing the non-compliant products, mandating companies to cease sales and usage, initiating product recalls, and requiring prompt rectification. The regulatory framework for these enforcement actions is based on Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. The State Food and Drug Administration (SFDA) further instructed local authorities to investigate the manufacturers for illegal activities related to producing and selling substandard drugs. A key requirement was the public disclosure of investigation results and penalties for involved enterprises within three months. Companies with objections regarding product authenticity were provided a formal process to dispute the findings with their provincial regulators, ensuring due process in maintaining drug quality and safety standards.

Company: https://www.globalkeysolutions.net/companies/xinxing-county-yongxiang-traditional-chinese-medicine-pieces-factory-co-ltd/c20f2209-df01-4bbe-8a52-3637bed7aaa3/